Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 21, 2011
Thu, October 20, 2011
00 a.m. ET to Discuss the Results of the Special Meeting of Stockholders Vote
LEXINGTON, Mass.--([ BUSINESS WIRE ])--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that following the Companya™s special meeting of stockholders that is taking place on October 21, 2011, at 9:00 a.m. ET., a press release will be issued with the results of the meeting, followed by a conference call and webcast at 10:00 a.m. ET.
Conference Call and Webcast Access
To access the conference call via telephone, dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay of the conference call will be available from approximately 1:00 p.m. ET on October 21 until midnight October 25. To access the replay, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 20957404.
Following the conference call, the webcast replay will be available at approximately 1:00 p.m. ET and will be archived on the Investors section of the AMAG Pharmaceuticals, Inc. website through midnight November 21, 2011.
Additional Information and Where You Can Find It
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. The proposed merger between AMAG and Allos will be submitted to the respective stockholders of AMAG and Allos for their consideration.
AMAG has filed a Registration Statement on Form S-4 containing a joint proxy statement/prospectus of Allos and AMAG and other documents concerning the proposed acquisition with the Securities and Exchange Commission (the aSECa). The SEC declared the Registration Statement on Form S-4 effective on September 14, 2011. Investors are urged to read the joint proxy statement/prospectus and other relevant documents filed with the SEC because they contain important information. Security holders may obtain a free copy of the proxy statement/prospectus and other documents filed by Allos and AMAG with the SEC at the SECa™s website at [ http://www.sec.gov ]. The joint proxy statement/prospectus and other documents may also be obtained for free by contacting Allosa™ Investor Relations by e-mail at [ investorrelations@allos.com ], by telephone at (303) 426-6262 or by mail at Investor Relations, Allos Therapeutics, Inc., 11080 CirclePoint Road, Suite 200, Westminster, CO 80020 or by contacting AMAGa™s Investor Relations by e-mail at [ asullivan@amagpharma.com ], by telephone at (617) 498-3303 or by mail at Investor Relations, AMAG Pharmaceuticals, Inc., 100 Hayden Avenue, Lexington, MA 02421.
Allos, AMAG, certain of their respective directors, executive officers, members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitation of proxies in connection with the proposed merger. Information regarding Allosa™ directors and executive officers and their beneficial ownership of Allosa™ common stock is also set forth in Allosa™ annual proxy statement on Schedule 14A filed with the SEC on April 29, 2011. This document is available free of charge at the SECa™s website at [ http://www.sec.gov ] or by going to Allosa™ Investors page on its corporate website at [ http://www.allos.com ]. Information concerning AMAGa™s directors and executive officers and their beneficial ownership of AMAGa™s common stock is set forth in AMAGa™s annual proxy statement on Schedule 14A filed with the SEC on April 18, 2011. This document is available free of charge at the SECa™s website at [ http://www.sec.gov ] or by going to AMAGa™s Investors page on its corporate website at [ http://www.amagpharma.com ]. Additional information regarding the persons who may, under the rules of the SEC, be deemed aparticipantsa in the solicitation of proxies in connection with the proposed merger, and a description of their direct and indirect interests in the proposed merger, which may differ from the interests of Allosa™ investors or AMAGa™s investors generally, are set forth in the joint proxy statement/prospectus filed with the SEC.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. For additional company information, please visit [ www.amagpharma.com ].
